Medicare AdvantageCoverageMedium impact
MA08.184, Cosibelimab-ipdl (Unloxcyt™)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
MA08.184 is a new pharmacy policy for Cosibelimab-ipdl (Unloxcyt™) effective July 28, 2025. This policy establishes coverage parameters, prior authorization requirements, and billing guidelines for this new biologic medication. The billing team must implement any prior authorization workflows and update systems to reflect this new covered service.
Action Required
By July 28, 2025: Billing team must review the complete MA08.184 policy text to identify specific HCPCS codes for Cosibelimab-ipdl (likely J-codes for biologics), prior authorization requirements, and any documentation requirements. Update billing system to enforce any prior auth workflows required by this policy. Verify that pharmacy claims for this medication are processed through the correct plan channels. Contact IBX for specific coding and authorization procedures if not detailed in policy. Flag any claims for this drug as new effective this date. Failure to implement prior authorization requirements will result in claim denials.